文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

AAV迷你抗肌萎缩蛋白基因治疗杜氏肌营养不良:1b期试验

AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trial.
PubMed 文献 · Nat Med · 2025-06-27

这项1b期多中心单臂开放标签试验评估了Fordadistrogene movaparvovec(PF-06939926)在杜氏肌营养不良(DMD)患者中的安全性和耐受性。可行走组最常见不良事件为呕吐、恶心等,3例治疗相关严重不良事件均在15天内缓解;非可行走组出现2例严重治疗相关不良事件(溶血性尿毒综合征和致死性心源性休克)。高剂量可行走组迷你抗肌萎缩蛋白阳性纤维比例从基线0.1%升至1年34.8%,作者认为该基因治疗在可行走人群中安全性可接受,但需更大规模试验评估疗效。

要点

  • 可行走组最常见治疗中出现的不良事件为呕吐(15例)、恶心(10例)和血小板减少(9例)。
  • 可行走组发生3例治疗相关严重不良事件(脱水、急性肾损伤、血小板减少),均在15天内缓解。
  • 非可行走组(n=3)出现溶血性尿毒综合征和致死性心源性休克两例严重治疗相关不良事件。

核心结论

  • 在1年主要完成时间点,Fordadistrogene movaparvovec在可行走人群中表现出可接受的安全性特征。
  • 需要更大规模的试验来评估该基因治疗在DMD中的疗效。

研究设计与样本

  • 1b期、多中心、单臂、开放标签试验,纳入可行走和非可行走参与者,报告1年数据。
  • 可行走组为接受稳定糖皮质激素治疗、经基因诊断的儿科男性DMD患者,接受单次静脉低剂量(n=3)或高剂量(n=16)Fordadistrogene movaparvovec。
  • 主要终点为给药后1年的安全性和耐受性。
  • 非可行走组样本量小(n=3),给药时平均±标准差年龄为15.1±1.0岁。

主要发现

  • 可行走组给药时平均±标准差年龄为8.6±1.6岁。
  • 可行走组最常见的治疗中出现的不良事件为呕吐(n=15)、恶心(n=10)、血小板减少(n=9)、发热(n=9)、食欲下降(n=8)、疲劳(n=7)和头痛(n=7)。
  • 可行走组给药后发生3例治疗相关严重不良事件(脱水、急性肾损伤、血小板减少),均在15天内缓解。
  • 非可行走组(n=3)最常见的治疗中出现的不良事件为恶心(n=3)、呕吐(n=3)和头痛(n=3),并观察到两例严重治疗相关不良事件(溶血性尿毒综合征和致死性心源性休克)。
  • 高剂量可行走组迷你抗肌萎缩蛋白阳性纤维百分比均值(95%置信区间)在基线、2个月和1年分别为0.1%(0.1-0.2)、20.3%(12.2-29.3)和34.8%(21.1-49.8)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 非可行走组样本量小(n=3)。
  • 需要更大规模的试验来评估该基因治疗在DMD中的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gene therapy represents a promising approach for Duchenne muscular dystrophy (DMD), a rare X-linked genetic muscle disease. Fordadistrogene movaparvovec (PF-06939926) is an adeno-associated virus serotype 9 gene therapy containing a miniaturized dystrophin being developed for DMD, which aims to restore functional protein to muscle. We present 1-year data from ambulatory and nonambulatory participants in a phase 1b, multicenter, single-arm, open-label trial. Pediatric ambulatory male participants with a genetic DMD diagnosis and receiving stable glucocorticoids received a single intravenous low-dose (n = 3) or high-dose (n = 16) fordadistrogene movaparvovec. The primary endpoint was safety and tolerability at 1 year after dosing. In the ambulatory group, mean ± s.d. age at dosing was 8.6 ± 1.6 years. The most common treatment-emergent adverse events in the ambulatory group were vomiting (n = 15), nausea (n = 10), thrombocytopenia (n = 9), pyrexia (n = 9), decreased appetite (n = 8), fatigue (n = 7) and headache (n = 7). Three treatment-related serious adverse events occurred after dosing (dehydration, acute kidney injury, thrombocytopenia; all resolved within 15 days). In a small nonambulatory group (n = 3), mean ± s.d. age at dosing was 15.1 ± 1.0 years. The most common treatment-emergent adverse events were nausea (n = 3), vomiting (n = 3) and headache (n = 3); two severe treatment-related adverse events (hemolytic uremic syndrome and fatal cardiogenic shock) were observed. In the high-dose ambulatory group, the secondary endpoint of mini-dystrophin quantification showed robust expression. Mean (95% confidence interval) percent of mini-dystrophin-positive fibers for baseline, 2 months and 1 year were 0.1% (0.1-0.2), 20.3% (12.2-29.3) and 34.8% (21.1-49.8), respectively. At the 1-year time point of primary completion, fordadistrogene movaparvovec demonstrated an acceptable safety profile in the ambulatory population. Larger trials are needed to assess the efficacy of the gene therapy in DMD. ClinicalTrials.gov registration no. NCT03362502 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Butterfield RJ, Shieh PB, Li H, et al. AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trial. Nat Med. 2025. PMID: 40579547. doi:10.1038/s41591-025-03750-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。